Who
David M. Rubenstein
Director
Company insider
Files Form 4 as: Director and Officer and 10% owner, The Carlyle Group; Director, Moderna.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $819.9M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Jan 2020
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code G | —100,000 at $0.00 | filing |
| 11 Sep 2026filed 11 Sep 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Sold | $17.1M400,000 at $42.74 | filing |
| 11 Sep 2026filed 11 Sep 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code G | —100,000 at $0.00 | filing |
| 11 Sep 2026filed 11 Sep 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Sold | $17.1M400,000 at $42.74 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,681 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,092 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,681 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,092 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —8,116 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,116 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,116 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —8,116 | filing |
| 19 Mar 2026filed 20 Mar 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code G | —100,000 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Sold | $23.3M500,000 at $46.68 | filing |
| 19 Mar 2026filed 20 Mar 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code G | —100,000 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Sold | $23.3M500,000 at $46.68 | filing |
| 10 Dec 2025filed 12 Dec 2025 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Code G | —625,000 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | CG The Carlyle GroupCapital Markets & Asset Management | SEC FORM 4 Sold | $35.3M625,000 at $56.55 | filing |
| 5 Aug 2025filed 6 Aug 2025 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —850 at $0.00 | filing |
| 5 Aug 2025filed 6 Aug 2025 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —850 | filing |
News
Library of Congress Publishes 'Speaking of America,' Featuring David M. Rubenstein's Congressional Dialoguesnewsroomamerica.com · 30 Sep 2026Carlyle Credit Income Fund Schedules Fourth Quarter and Full Year 2026 Financial Results and Investor Conference CallCG · manilatimes.net · 22 Oct 2026Carlyle Group (NASDAQ:CG) Given New $48.00 Price Target at Piper SandlerCG · dailypolitical.com · 19 Oct 2026Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the Third Quarter Ended September 30, 2026CG · manilatimes.net · 16 Oct 2026
1 headline in the last 90 days name David M. Rubenstein; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.